# US 2023/0056577 A1 · Crispr-associated transposase systems and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056577 A1
- Document ID: US20230056577A1
- Status: Published application
- Kind: A1
- Application number: 17/742,503
- Filed: 2022-05-12
- Published: 2023-02-23
- Earliest claimed: 2018-12-17
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology
- Applicants: The Broad Institute, Inc.; Massachusetts Institute of Technology
- Inventors: Feng Zhang; Jonathan Strecker; Alim Ladha
- Web page: https://patentgrep.com/patent/US20230056577A1

## CPC

- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C07K 14/195: from bacteria
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/85: for animal cells
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A delivery system configured to deliver one or more components of an engineered nucleic acid targeting system comprising:
(a) one or more CRISPR-associated Tn7 transposase or Tn7-like transposase proteins that form a transposase;
(b) a catalytically inactive Type V Cas protein capable of forming a complex with the transposase;
(c) a guide molecule capable of forming a complex with the Type V Cas protein and directing sequence-specific binding of a guide-Cas protein complex to a target sequence of a target polynucleotide; and
(d) a donor construct, comprising a heterologous donor polynucleotide sequence flanked by a first and second binding sequence capable of complexing the donor construct with the one or more Tn7 or Tn7-like transposase proteins.

### Claim 30 (depends on 29)

The delivery system of claim 29, further comprising one or more vectors.

### Claim 31 (depends on 30)

The delivery system of claim 30, wherein the one or more vectors comprise one or more polynucleotides encoding components (a), (b), and (c).

### Claim 32 (depends on 31)

The delivery system of claim 31, wherein components (a), (b), and (c) are on the same vector.

### Claim 33 (depends on 31)

The delivery system of claim 31, wherein components (a), (b), and (c) are on different vectors.

### Claim 34 (depends on 31)

The delivery system of claim 31, wherein components (a) and (b) are on a first vector and component (c) is on a second vector.

### Claim 35 (depends on 31)

The delivery system of claim 31, wherein component (a) is on a first vector and components (b) and (c) are on a second vector.

### Claim 36 (depends on 31)

The delivery system of claim 31, wherein the one or more polynucleotides are codon optimized for expression in a eukaryotic cell.

### Claim 37 (depends on 30)

The delivery system of claim 30, wherein the one or more vectors comprise one or more viral vectors further comprising one or more polynucleotides encoding components (a), (b), and (c).

### Claim 38 (depends on 37)

The delivery system of claim 37, wherein the one or more viral vectors comprise retroviral, lentiviral, adenoviral, adeno-associated, or herpes simplex viral vectors.

### Claim 39 (depends on 31)

The delivery system of claim 31, wherein component (a) comprises (i) TnsB and TnsC, or (ii) TniA and TniB.

### Claim 40 (depends on 39)

The delivery system of claim 39, wherein TnsB and TnsC are on the same vector or on different vectors.

### Claim 41 (depends on 40)

The delivery system of claim 40, wherein components (b) and (c), TnsB, and TnsC are on the same vector.

### Claim 42 (depends on 40)

The delivery system of claim 40, wherein components (b) and (c), and either TnsB or TnsC are on the same vector.

### Claim 43 (depends on 39)

The delivery system of claim 39, wherein TniA and TniB are on the same vector or on different vectors.

### Claim 44 (depends on 43)

The delivery system of claim 43, wherein components (b) and (c), TniA, and TniB are on the same vector.

### Claim 45 (depends on 43)

The delivery system of claim 43, wherein components (b) and (c), and either TniA or TniB are on the same vector.

### Claim 46 (depends on 31)

The delivery system of claim 31, wherein component (a) comprises:
(i) TnsA, TnsB, TnsC, and TniQ;
(ii) TnsA, TnsB, and TnsC;
(iii) TnsB, TnsC, and TniQ;
(iv) TnsA, TnsB, and TniQ;
(v) TnsE;
(vi) TniA, TniB, and TniQ;
(vii) TnsB, TnsC, and TnsD;
(viii) TnpA; or
(ix) any combination thereof.

### Claim 47 (depends on 46)

The delivery system of claim 46, wherein one or more of subcomponents (i)-(ix) are on the same vector or on different vectors.

### Claim 48 (depends on 31)

The delivery system of claim 31, wherein component (a) comprises TnsB, TnsC, and TniQ.

### Claim 49 (depends on 43)

The delivery system of claim 43, wherein TnsB, TnsC, and TniQ are on the same vector or on different vectors.

### Claim 50 (depends on 49)

The delivery system of claim 49, wherein components (b) and (c), and one or more of TnsB, TnsC, and TniQ are on the same vector.

### Claim 51 (depends on 48)

The delivery system of claim 48, wherein the TnsB, TnsC, and TniQ are proteins selected from Table 28 or Table 29, or are encoded by polynucleotides selected from Table 26 or Table 27.

### Claim 52 (depends on 29)

The delivery system of claim 29, wherein the Type V Cas protein comprises Cas12k.

### Claim 53 (depends on 51)

The delivery system of claim 51, wherein the Cas12k is encoded by a polynucleotide selected from Table 26 or Table 27; or is a protein selected from Table 28 or Table 29; or is selected from an organism of FIGS. 2A and 2B or Table 2.

### Claim 54 (depends on 29)

The delivery system of claim 29, wherein the guide molecule comprises a polynucleotide sequence selected from Table 26.
